1 |
Weller, M., S. Winter, C. Schmidt, P. Esser, A. Fontana, J. Dichgans, and P. Groscurth. 1997. Topoisomerase-I inhibitors for human malignant glioma: differential modulation of p53, p21, bax and bcl-2 expression and of CD95-mediated apoptosis by camptothecin and -lapachone. Int. J. Cancer 73, 707-714.
DOI
|
2 |
Wuerzberger, S. M., J. J. Pink, S. M. Planchon, K. L. Byers, W. G. Bornmann, and D. A. Boothman. 1998. Induction of apoptosis in MCF-7:WS8 breast cancer cells by -lapachone. Cancer Res. 58, 1876-1885.
|
3 |
Noble, J. R., K. E. Willetts, W. E. Mercer, and R. R. Reddel. 1992. Effects of exogenous wild-type p53 on a human lung carcinoma cell line with endogenous wild-type p53. Exp. Cell Res. 203, 297-304.
DOI
|
4 |
Pink, J. J., S. M. Planchon, C. Tagliarino, M. E. Varnes, D. Siegel, and D. A. Boothman. 2000. NAD(P)H:Quinone oxidoreductase activity is the principal determinant of -lapachone cytotoxicity. J. Biol. Chem. 275, 5416-5424.
DOI
|
5 |
Schaffner-Sabba, K., K. H. Schmidt-Ruppin, W. Wehrli, A. R. Schuerch, and J.W. Wasley. 1984. -lapachone: synthesis of derivatives and activities in tumor models. J. Med. Chem. 27, 990-994.
DOI
|
6 |
Planchon, S. M., J. J. Pink, C. Tagliarino, W. G. Bornmann, M. E. Varnes, and D. A. Boothman. 2001. -lapachone-induced apoptosis in human prostate cancer cells: involvement of NQO1/xip3. Exp. Cell Res. 267, 95-106.
DOI
|
7 |
Planchon, S. M., S. Wuerzberger, B. Frydman, D. T. Witiak, P. Hutson, D. R. Church, G. Wilding, and D. A. Boothman. 1995. -lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: a p53-independent response. Cancer Res. 55, 3706-3711.
|
8 |
Planchon, S. M., S. M. Wuerzberger-Davis, J. J. Pink, K. A. Robertson, W. G. Bornmann, and D. A. Boothman. Bcl-2 protects against -lapachone-mediated caspase 3 activation and apoptosis in human myeloid leukemia (HL-60) cells. Oncol. Rep. 6, 485-492.
|
9 |
Weller, M., J. Rieger, C. Grimmel, E.G. Van Meir, N. De Tribolet, S. Krajewski, J. C. Reed, A. von Deimling, and J. Dichgans. 1998. Predicting chemoresistance in human malignant glioma cells: the role of molecular genetic analyses. Int. J. Cancer 79, 640-644.
DOI
|
10 |
Fujita, H., K. Koshida, E. T. Keller, Y. Takahashi, T. Yoshimito, M. Namiki, and A. Mizokami. 2002. Cyclooxygenase-2 promotes prostate cancer progression. Prostate 53, 232-240.
DOI
|
11 |
Gately, S. and R. Kerbel. 2003. Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis. Prog. Exp. Tumor. Res. 37, 179-192.
DOI
|
12 |
Huang, L., and A. B. Pardee. 1999. -lapachone induces cell cycle arrest and apoptosis in human colon cancer cells. Mol. Med. 5, 711-720.
|
13 |
Hueber, A. P. Esser, K. Heimann, N. Kociok, S. Winter, and M. Weller. 1998. The topoisomerase I inhibitors, camptothecin and -lapachone, induce apoptosis of human retinal pigment epithelial cells. Exp. Eye Res. 67, 525-530.
DOI
|
14 |
Lee, J. H., J. Cheong, Y. M. Park, and Y. H. Choi. 2005. Down-regulation of cyclooxygenase-2 and telomerase activity by -lapachone in human prostate carcinoma cells. Pharmacol. Res. 51, 553-560.
DOI
|
15 |
Lee, J. I., D. Y. Choi, H. S. Chung, H. G. Seo, H. J. Woo, B. T. Choi, and Y. H. Choi. 2006. -lapachone induces growth inhibition and apoptosis in bladder cancer cells by modulation of Bcl-2 family and activation of caspases. Exp. Oncol. 28, 30-35.
|
16 |
Li, C. J., L. Averboukh, and A. B. Pardee. 1993. -Lapachone, a novel DNA topoisomerase I inhibitor with a mode of action different from camptothecin. J. Biol. Chem. 268, 22463-22468.
|
17 |
Meng, R. D. and W. S. El-Deiry. 2001. p53-independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-. Exp. Cell Res. 262, 154-169.
DOI
|
18 |
Moon, D. O., Y.H. Choi, N. D. Kim, Y.M. Park, and G. Y. Kim. 2007. Anti-inflammatory effects of -lapachone in lipopolysaccharide-stimulated BV2 microglia. Int. Immunopharmacol. 7, 506-514.
DOI
|
19 |
Anderson, W. F., A. Umar, J. L. Viner, and E. T. Hawk. 2002. The role of cyclooxygenase inhibitors in cancer prevention. Curr. Pharm. 8, 1035-1062.
DOI
|
20 |
Choi, Y. H., H. S. Kang, and M. A. Yoo. 2002. Suppression of Human Prostate Cancer Cell Growth by -lapachone via Inhibition of pRB Phosphorylation and Induction of Cdk inhibitor p21. J. Biochem. Mol. Biol. 36, 223-229.
|
21 |
Choi, Y. H., M. J. Kim, S. Y. Lee, Y. N. Lee, G. Y. Chi, H. S. Eom, N. D. Kim, and B. T. Choi. 2002. Phosphorylation of p53, induction of Bax and activation of caspases during -lapachone-mediated apoptosis in human prostate epithelial cells. Int. J. Oncol. 21, 1293-1299.
|
22 |
Don, M. J., Y. H. Chang, K. K. Chen, L. K. Ho, and Y. P. Chau. 2001. Induction of CDK inhibitors (p21(WAF1) and p27(Kip1)) and Bak in the -lapachone-induced apoptosis of human prostate cancer cells. Mol. Pharmacol. 59, 784-794.
|